---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-057078"
form_type: "8-K"
ticker: "CBIO"
cik: "0001253689"
company_name: "CRESCENT BIOPHARMA, INC."
filed_at: "2025-06-06T23:59:59+00:00"
generated_at: "2026-05-19T18:06:40.547755+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Stockholders approve merger with Crescent Biopharma; 1-for-100 reverse split

## Summary
- Stockholders approved all 10 proposals including merger agreement, stock issuance, charter amendments, reverse split, and equity plans.
- Board approved 1-for-100 reverse stock split; outstanding shares reduced from ~64.5M to ~0.6M.
- Post-merger combined company to trade as Crescent Biopharma, Inc. (CBIO) on Nasdaq starting June 16, 2025.
- Combined company expected to have ~14.8M shares outstanding (~25.3M fully diluted) post-merger.

## SEC filing metadata
- accession: 0001104659-25-057078
- form_type: 8-K
- ticker: CBIO
- cik: 0001253689
- company_name: CRESCENT BIOPHARMA, INC.
- filed_at: 2025-06-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.07, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1253689/000110465925057078/0001104659-25-057078-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1253689/000110465925057078/tm2517051d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-057078
- JSON: https://secwatch.observer/filing/0001104659-25-057078.json
- Plain text: https://secwatch.observer/filing/0001104659-25-057078.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.